Whiteaker Jeffrey R, Halusa Goran N, Hoofnagle Andrew N, Sharma Vagisha, MacLean Brendan, Yan Ping, Wrobel John A, Kennedy Jacob, Mani D R, Zimmerman Lisa J, Meyer Matthew R, Mesri Mehdi, Boja Emily, Carr Steven A, Chan Daniel W, Chen Xian, Chen Jing, Davies Sherri R, Ellis Matthew J C, Fenyö David, Hiltke Tara, Ketchum Karen A, Kinsinger Chris, Kuhn Eric, Liebler Daniel C, Liu Tao, Loss Michael, MacCoss Michael J, Qian Wei-Jun, Rivers Robert, Rodland Karin D, Ruggles Kelly V, Scott Mitchell G, Smith Richard D, Thomas Stefani, Townsend R Reid, Whiteley Gordon, Wu Chaochao, Zhang Hui, Zhang Zhen, Rodriguez Henry, Paulovich Amanda G
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N., Seattle, WA, 98109, USA.
Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
Methods Mol Biol. 2016;1410:223-36. doi: 10.1007/978-1-4939-3524-6_13.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI) has launched an Assay Portal (http://assays.cancer.gov) to serve as an open-source repository of well-characterized targeted proteomic assays. The portal is designed to curate and disseminate highly characterized, targeted mass spectrometry (MS)-based assays by providing detailed assay performance characterization data, standard operating procedures, and access to reagents. Assay content is accessed via the portal through queries to find assays targeting proteins associated with specific cellular pathways, protein complexes, or specific chromosomal regions. The position of the peptide analytes for which there are available assays are mapped relative to other features of interest in the protein, such as sequence domains, isoforms, single nucleotide polymorphisms, and posttranslational modifications. The overarching goals are to enable robust quantification of all human proteins and to standardize the quantification of targeted MS-based assays to ultimately enable harmonization of results over time and across laboratories.
美国国立癌症研究所（NCI）的临床蛋白质组肿瘤分析联盟（CPTAC）已推出一个分析门户（http://assays.cancer.gov），作为一个特征明确的靶向蛋白质组分析的开源存储库。该门户旨在通过提供详细的分析性能表征数据、标准操作程序和试剂获取途径，来管理和传播高度特征化的基于靶向质谱（MS）的分析方法。通过在门户中进行查询，可获取分析内容，以找到针对与特定细胞途径、蛋白质复合物或特定染色体区域相关蛋白质的分析方法。针对可用分析方法的肽分析物的位置，相对于蛋白质中其他感兴趣的特征进行了映射，如序列结构域、异构体、单核苷酸多态性和翻译后修饰。总体目标是实现对所有人类蛋白质的可靠定量，并使基于靶向MS的分析方法的定量标准化，最终实现不同时间和不同实验室结果的统一。
